Henry Schein Medical GmbH
Pharmaceutical Companies · Berlin
Henry Schein Medical GmbH is a pharmaceutical company based in Berlin, Berlin, Germany. The company operates in the German pharmaceutical market and is regulated by the BfArM (Federal Institute for Drugs and Medical Devices).
Content in German
The detailed company information on this page is provided in the original German language. You can use your browser's built-in translation feature to view it in English.
Right-click on the page and select "Translate to English" or use the translation icon in your browser's address bar.
Henry Schein Medical GmbH Address & Contact
Company profile
1932
Founded
22.000+ (global)
Employees
Henry Schein Medical GmbH Overview
Henry Schein Medical GmbH is the German subsidiary of the globally operating Henry Schein Inc., a leading provider of health solutions for medical and dental professionals. Based in Berlin, the company plays a key role in the German market for medical and dental products. The corporate group was founded in 1932 and has developed over the decades into one of the largest providers in the healthcare industry, operating in over 30 countries and serving more than 1 million customers.
Medical Products and Practice Supplies
Henry Schein Medical offers a comprehensive range of products and services specifically tailored to the needs of medical practices, hospitals, and outpatient facilities. The product range includes, among others:
- Medical Devices: These include ultrasound machines, X-ray systems, and laboratory equipment that meet current technological standards.
- Diagnostic Tests: This includes test kits for infectious diseases, chemical and clinical tests that enable rapid and accurate diagnostics.
- Consumables: Henry Schein offers consumable supplies such as gloves, masks, sterilization units, and dressing materials that are essential for daily use.
- Practice Management Solutions: These include digital solutions to optimize operational processes in medical practices, including software for appointment scheduling, billing, and patient management.
Additionally, the company maintains a range of pharmaceutical products that meet the needs of medical practices regarding commonly used medications. Through direct cooperation with manufacturers and suppliers, Henry Schein ensures high availability and competitiveness of the products.
Regulatory Classification
Henry Schein Medical operates within the strict regulatory framework applicable in the European Union and specifically in Germany for medical devices and pharmaceutical products. The company meets the requirements of the European regulations for medical devices (MDR) and the drug legislation (AMG). Quality assurance is ensured through internally defined standards and independent audits, ensuring that all products comply with legal requirements and guarantee user safety. Furthermore, Henry Schein has an effective risk management system that identifies potential hazards early and implements appropriate measures for risk reduction.
Location Berlin
Berlin, as the capital and a significant center for healthcare in Germany, provides ideal conditions for the activities of Henry Schein Medical. The city has a high density of medical facilities, including numerous practices, specialist clinics, and research institutions. The central location allows Henry Schein to efficiently manage both the field service and e-commerce sales, maintaining close contact with customers.
Additionally, the Berlin location has strategic advantages regarding logistics and access to innovative technological developments due to its proximity to universities and healthcare facilities. Henry Schein leverages these synergies to develop new products and services that meet the changing demands of the healthcare market.
Features and Future Perspectives
One outstanding feature of Henry Schein Medical is its focus on innovation and digitization in healthcare. The company continuously invests in modern technologies to optimize workflows in practices and improve patient care. This includes the development of telemedicine systems and the integration of artificial intelligence in diagnostics and patient management.
The future prospects for Henry Schein in Germany are promising. Given the increasing demand for healthcare services and changing technologies, the company will continue to work on expanding its product range and tapping into new market segments. Active participation in innovation processes in the healthcare industry will position Henry Schein as a leader and further enhance its contribution to the quality of medical care in Germany.
More Pharmaceutical Companies in Germany | Pharmaceutical Companies in Berlin | Medical Technology in Berlin
```Frequently asked questions about Henry Schein Medical GmbH
What does Henry Schein Medical GmbH do?
Henry Schein Medical GmbH is ein medizinischer Fachhandel with rangeen zu Praxisbedarf, technischen facilityen and carebedarf. Dienstleisungen are Reparatur and Wartung the gelieferten Geräte sowie messtechnische and sicherheitstechnische Kontrollen. Leasingverträge are daat möglich. Als Eigenmarke offers er zusätzlich Desinfektionswithtel an.
Henry Schein Medical GmbH on social media
More Pharmaceutical Companies in Berlin
Pharmaceutical Companies in Germany
Related areas in healthcare
Pharmaceutical Companies by location
About Pharmaceutical Companies
Germany is one of the world's leading pharmaceutical nations, home to more than 1,000 pharmaceutical businesses employing approximately 130,000 people (vfa 2023). Companies operating in this sector develop, manufacture and distribute medicines across the entire value chain, from early-stage research and clinical trials through to market authorisation and commercial distribution. In Germany, every manufacturer of medicinal products must hold a manufacturing authorisation (Herstellungserlaubnis) issued under Section 13 of the AMG (Arzneimittelgesetz, Germany's Medicinal Products Act). Medicines may only be placed on the market after receiving approval from either BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Germany's Federal Institute for Drugs and Medical Devices, broadly comparable to the FDA in the United States or the MHRA in the United Kingdom) or the European Medicines Agency (EMA) via the centralised procedure. All manufacturing sites are subject to regular GMP (Good Manufacturing Practice) inspections carried out by the competent pharmaceutical supervisory authority of the relevant German federal state. The sector covers prescription-only medicines (Rx), non-prescription OTC products, generics, biosimilars and active pharmaceutical ingredients (APIs). This directory lists pharmaceutical manufacturers, marketers and licence holders across all German federal states with full contact details, addresses and phone numbers.
Germany's Pharmaceutical Industry
Germany is consistently ranked among the top five pharmaceutical markets worldwide, generating annual revenues exceeding EUR 50 billion and accounting for the largest share of pharmaceutical production in continental Europe. The industry is represented by two major associations: vfa (Verband Forschender Arzneimittelhersteller), which represents research-based companies, and BAH (Bundesverband der Arzneimittel-Hersteller), which represents the broader manufacturer base including OTC and self-medication products. German pharmaceutical companies cover the full spectrum from global innovator corporations and mid-sized specialty manufacturers to generic producers and biotech firms. The country is a world leader in active pharmaceutical ingredient (API) production, biologics manufacturing and pharmaceutical chemistry. Key therapeutic areas of strength include oncology, cardiovascular medicine, immunology, neuroscience and rare diseases. Germany also serves as a significant export hub, with pharmaceutical products among the country's leading export categories. The sector benefits from a highly skilled workforce, world-class university research institutions and a dense network of research hospitals (Universitätsklinika) that facilitate clinical trial activity.
Regulatory Framework: BfArM, EMA and the AMG
The legal foundation for pharmaceutical activity in Germany is the Arzneimittelgesetz (AMG, German Medicinal Products Act), which regulates the authorisation, manufacture, import, distribution, labelling and pharmacovigilance of medicinal products. For English-speaking readers unfamiliar with the German regulatory landscape: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is the national competent authority responsible for approving medicines marketed only in Germany, supervising narcotics, and maintaining the pharmacovigilance database. BfArM is a higher federal authority (Bundesoberbehörde) subordinate to the Federal Ministry of Health (Bundesministerium für Gesundheit). For medicines approved via the centralised EU procedure, the European Medicines Agency (EMA) grants a single marketing authorisation valid in all 27 EU member states. Germany is also home to the Paul-Ehrlich-Institut (PEI), a second federal authority that specifically handles biological medicines including vaccines, blood products and gene therapy products. Manufacturing sites are inspected by state-level pharmaceutical supervisory authorities (Landesbehörden) to verify GMP compliance, with findings entered into the EudraGMDP database operated by the EMA.
Regional Pharmaceutical Clusters in Germany
Germany's pharmaceutical industry is geographically distributed across several major regional clusters. The Rhine-Main area around Frankfurt and Leverkusen in North Rhine-Westphalia is home to some of Germany's largest pharmaceutical sites, including facilities belonging to global corporations with long histories in German chemistry and pharmaceuticals. Bavaria (particularly Munich, Penzberg and Marburg) is a second major hub, especially strong in biotechnology and biologics production. Baden-Württemberg, including cities such as Mannheim, Heidelberg and Biberach an der Riss, is home to several significant research-based manufacturers. Hamburg and the northern German region have a cluster of specialty and generic manufacturers. Berlin has a growing biotech scene connected to its research universities and the Charité hospital. Hesse is notable for its proximity to Frankfurt's logistics infrastructure and several major API manufacturers. Smaller but significant clusters exist in Saxony (Leipzig, Dresden) and Lower Saxony, benefiting from proximity to university research centres and historically established chemical industry sites.
Drug Classes and Product Segments
German pharmaceutical companies cover all major drug classes. Prescription (Rx) products account for the largest share of revenue; generics manufacturers such as Stada, ratiopharm (Teva) and Hexal produce chemically equivalent alternatives after patent expiry, significantly reducing costs for the healthcare system. Biologics and biosimilars are gaining ground rapidly: monoclonal antibodies, insulin analogues and recombinant growth factors require specialised biotech manufacturing facilities. OTC products (over-the-counter), i.e. medicines available without a prescription, represent a multi-billion-euro market served by companies such as Bayer Consumer Health, Stada and Klosterfrau. Homeopathic preparations, herbal medicines and dietary supplements form further regulated segments. Digitalisation is increasingly shaping the sector: Digital Health Applications (DiGA) have been reimbursable since 2020, and AI-assisted drug development is significantly shortening time-to-market.
What does a pharmaceutical company do?
Pharmaceutical companies develop, produce and distribute medicines. They cover the entire value chain from research and clinical trials through to market launch and distribution. In Germany, they are supervised by BfArM (the Federal Institute for Drugs and Medical Devices, comparable to the FDA or MHRA).
How are pharmaceutical companies regulated in Germany?
Pharmaceutical companies in Germany must hold a manufacturing authorisation under Section 13 of the AMG (German Medicinal Products Act). All authorised medicines require approval from either BfArM or the European Medicines Agency (EMA). Regular GMP (Good Manufacturing Practice) inspections ensure quality standards are maintained.
Where can I find contact details for pharmaceutical companies in Germany?
Industry associations such as vfa (Association of Research-Based Pharmaceutical Companies) and BPI (Federal Association of the German Pharmaceutical Industry) maintain member directories. Many companies also list their key contacts directly on their websites. Sanoliste provides a searchable directory of pharmaceutical companies in Germany sorted by federal state and city.
How many pharmaceutical companies are there in Germany?
Germany is home to more than 1,000 pharmaceutical companies employing approximately 130,000 people, according to vfa (the Association of Research-Based Pharmaceutical Companies) 2023 data. The sector includes multinational corporations, mid-sized specialty firms, generic manufacturers and biotech startups.
What is BfArM and what does it regulate?
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is Germany's Federal Institute for Drugs and Medical Devices. It is a higher federal authority within the portfolio of the Federal Ministry of Health and is responsible for approving medicines for the German market, monitoring drug safety (pharmacovigilance), regulating narcotics and controlled substances, and overseeing medical devices in Germany. It is broadly comparable to the FDA in the United States or the MHRA in the United Kingdom.
What is the difference between BfArM approval and EMA approval?
Medicines in Germany can be approved through two main routes. BfArM grants national marketing authorisations valid in Germany, or decentralised and mutual recognition procedure approvals valid in multiple EU states. The EMA (European Medicines Agency) grants centralised marketing authorisations valid in all 27 EU member states simultaneously, typically used for innovative biologic medicines, oncology drugs and products for rare diseases.
What does GMP mean in the context of German pharmaceutical manufacturing?
GMP stands for Good Manufacturing Practice. In Germany and the EU, GMP compliance is a legal requirement for all pharmaceutical manufacturers under the AMG and the EU GMP Guidelines (EudraLex Volume 4). GMP covers all aspects of production including premises, equipment, personnel qualification, process validation, documentation and quality control. Compliance is verified by regular inspections from the competent state pharmaceutical supervisory authority.